Who We Are Vital Biopharmaceutical Insights and Analytics written for Experts by Experts

12/08/2013

A Privately Owned $150m business

85% of our staff are dedicated to building and delivering our Content

Partner of choice for 48 of the top 50 Pharma…and have been for some time

A Premium yet cost-effective offering for small and mid-tier Biotech/Pharma

Over 3 decades working exclusively in Pharmaceuticals

and Med Devices

660 Staff located across 12 offices worldwide

What differentiates us from our competitors…

3

Network of Experts • Physicians • KOLs • Payers • Caregivers • Patient Advocacy Groups • Industry leaders

Unparalleled Therapy Area Coverage In Oncology, Immunology, CV-MET, Ophthalmology, CNS Depth of Therapy Area specific Emerging Market Analysis

Biopharmaceutical Focus

Analyst Team 80+ Analysts Longest tenure in the industry Recruited from Tier 1&2 Schools Industry & Academic Backgrounds

Five Research Streams Therapy Strategy Company Market Access Multi-Channel Strategies

Epidemiology (10 – 20 Year Forecasts & Historical data) 13 Epidemiologists >130 indications (>2300 patient populations) Only company to quantify drug-treatable as standard Patient populations to the fourth line of therapy in cancer

Primary Market Research 2013 7MMs & EMs 160 PMR Studies|+15’500 Drs |+750 Payers |500 Pts. |+1000 KOLs Foundation of our Insights & Analysis Commission and conduct more research than our competitors

Market Access Coverage Country profiling Extensive International Payer Research Detailed Tx specific major & emerging market analysis

12/08/2013

6

PatientBase: The Source for Reliable, Comprehensive, and Up-to-Date Epidemiology Data, Analysis and Advisory Service

PatientBase covers more than 120 disease indications and 2300 patient populations (see Appendix 2 for full overview by Therapeutic Area)

Disease growth trends (annual) over a 20-year outlook period (10-year outlook for emerging markets coverage and select indications). Base year is 2011 and moved to 2012 in Q2 2013. Past-year data is available on request for many indications Includes stratification of the patient population by:

Gender and age cohort Diagnosed and drug-treated status Relevant clinical variables such as stage of disease at diagnosis and severity Urban and rural status (for China and India)

The database is updated continuously throughout the year. Depending in the dynamicsof the market the indications are updated every 1 to 3 years.

Key questions that the service can help answer: • What is the size of a specific patient population across various geographies? • What factors will drive growth in a specific patient population? • Within a given patient population, how many are cases are drug-treated? • Which specific factors might influence future changes in drug-treatment? • Age and gender details by indication

7

Enhanced Content Expanded coverage: detailed analysis for ~2300 populations Extended forecasts: 20 year forecasts for most populations Expanded Emerging Markets coverage: new diseases and countries (see Appendix 3)

Increased transparency in methodology More summary graphics and high-level comparisons

Enhanced Navigation Highly integrated content provides convenient and intuitive navigation Better search capabilities: get to what you want in one or two clicks All Epi in One Place: Mature and Emerging Markets in the same platform

Enhanced Functionality Faster and more flexible data exporting capabilities Better data filters to customize tables, charts, and downloads

PatientBase is on the New Decision Resources Industry Opportunity Platform: Enhanced Content, Navigation and Functionality

8

Enhanced Content Expanded coverage: detailed analysis for ~2300 populations Extended forecasts: 20 year forecasts for most populations Expanded Emerging Markets coverage: new diseases and countries Increased transparency in methodology More summary graphics and high-level comparisons

Enhanced Navigation Highly integrated content provides convenient and intuitive navigation Better search capabilities: get to what you want in one or two clicks All Epi in One Place: Mature and Emerging Markets in the same platform

Enhanced Functionality Faster and more flexible data exporting capabilities Better data filters to customize tables, charts, and downloads

PatientBase on the New Decision Resources Industry Opportunity Platform: Enhanced Content, Navigation and Functionality

9

Enhanced Content Expanded coverage: detailed analysis for ~2300 populations Extended forecasts: 20 year forecasts for most populations Expanded Emerging Markets coverage: new diseases and countries Increased transparency in methodology More summary graphics and high-level comparisons

Enhanced Navigation Highly integrated content provides convenient and intuitive navigation Better search capabilities: get to what you want in one or two clicks All Epi in One Place: Mature and Emerging Markets in the same platform

Enhanced Functionality Faster and more flexible data exporting capabilities Better data filters to customize tables, charts, and downloads

PatientBase on the New Decision Resources Industry Opportunity Platform: Enhanced Content, Navigation and Functionality

10

Mature vs. Emerging Markets

Full transparency on methodology and definitions

Granular epi on relevant

subpopulations

Easy download

Contact our analysts for peer discussion at no additional cost

11

Stratification by age and/or gender

Excel download in one click

Downloadable graphics

Forecast 20 years out

12/08/2013

DRG’s syndicated offering spans all stages of the product lifecycle

Supporting Pre-Clinical Through Maturity

Phase II Launch Phase III Submission Growth Maturity Phase I

Drug Development, Market Sizing & Emerging Market Assessments

Corporate Strategy and Competitive Intelligence

Brand Management - Outpatient and Institutional

C t St t d

Regulatory Approval , Market Access and Policy

Preclinical

Digital Marketing and non-Personal Promotion

Biosimilars

Major & Emerging Market Coverage:

US UK France Germany Italy Spain Japan China India Brazil Russia Mexico South Korea Turkey Canada Argentina Venezuela Poland Australia Indonesia Thailand Taiwan South Africa Saudi Arabia

COMPANY CONFIDENTIAL 3

Our Syndicated Report Offering provides a compelling value proposition

Market Planning Process DRG Product Offering Description Regional Coverage

Drug Development and Market Forecasting

Pharmacor

Disease market landscape and 10-year forecasts across G7 markets, including treatment patterns of existing and emerging therapies. This report forecasts the clinical and commercial outlook for drugs currently in the market and in development

US | EU5 | Japan

DecisionBase

An assessment of disease unmet need based on primary market research with physicians and MCOs, including a target product profile assessment for existing and emerging therapies. This report assesses the ability of key products in development to fulfill unmet needs and the clinical attributes required to capitalise on it

US | EU5 | Japan

Biosimilars Advisory Service

Clinical and commercial analysis of the threat of biosimilars to blockbuster Oncology biologic agents. This service highlights highlights critical trends in strategic development and monitors the ever-changing dynamics in commercially lucrative market segments

G7 (Asia & LATAM due in Dec 2013)

Brand Positioning, Perception and Update

LaunchTrends

LaunchTrends® tracks the trial, adoption, and usage during a product’s initial market introduction. Fielding occurs at one, three, six and twelve months post launch. LaunchTrends® provide information on how new products fit into the treatment algorithm, impact on current therapies, and change in market dynamics. LaunchTrends® employ a blend of quantitative and qualitative methods

US

TreatmentTrends

TreatmentTrends® provide insight into practice patterns, attitudes and perceptions of physicians as well as current and projected use of various products. They evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players. They are quantitative with several open-ended questions for qualitative feedback.

US| EU | Latin America

COMPANY CONFIDENTIAL 4

Our customers have flexibility to choose which product lines they access

Market Planning Process DRG Product Offering Description Regional Coverage

Market Access, Pricing and Reimbursement

Physician & Payer Forum (US)

Through primary research with physicians and MCO directors, US PPF helps our customers understand the impact of U.S. reimbursement hurdles for current and emerging therapies

US

Physician & Payer Forum (EU)

Uses primary research with physicians and national payers to detail the reimbursement legislation, process and hurdles in the EU5 EU5

Physician & Payer Forum (Emerging Markets)

Uses primary research with physicians and government officials to uncover the impact of reimbursement hurdles to brand success in key emerging markets

BRIC | Mexico | South Korea

Market Access Tracker Continuously updated analysis and advisory calls on the key legislative and commercial hurdles to gaining reimbursement within 24 mature and emerging markets

Americas | Europe | Asia-Pac | Middle East & Africa

Digital Marketing Landscape

Taking the Pulse Syndicated market research study and advisory service focused on information technology, new media and alternative channel adoption among physicians and nurses.

US | EU5 | Japan |BRIC | South Korea | Taiwan | Mexico | Canada

ePharma Physician and Consumer

Annual market research study and syndicated advisory service focused on information technology, new media and alternative channel adoption by physicians and consumer online research of pharmaceuticals

US

Specialist Segmentation Comprehensive profile of specific physician specialty audience and its use of information technology and digital media in the clinical practice setting

US

Cybercitizen Syndicated multi-client consumer study and advisory service focused on key research topics and trends at the intersection of technology and healthcare

US | EU5

A selection of our Oncology Titles Breadth and Depth from the go-to Industry source

12/08/2013 5

Pharmacor: • Breast Cancer • NSCLC • Prostate Cancer • Malignant Melanoma • Ovarian Cancer • Pancreatic Cancer • Glioblastoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Gastric Cancer • Colorectal Cancer • Renal Cell Carcinoma • Chronic Myeloid Leukemia

Niche Markets & Rare Diseases: • Bladder Cancer • Hepatocellular Carcinoma • Thyroid Cancer • Acute Lymphoblastic Leukemia • Acute Myeloid Leukemia • Soft Tissue Sarcoma • Squamous Cell Carcinoma of the Head and Neck • Myelodysplastic Syndrome

DecisionBase:

• Renal Cell Carcinoma (Advanced, Pre-Treated) • Small Cell Lung Cancer (Extensive-Stage Disease) • Breast Cancer (HER2-/HR+, Advanced/Metastatic) • Multiple Myeloma (Relapsed/Refractory) • Prostate Cancer (Metastatic, Castrate Resistant, 2nd - and

Subsequent-Line) • Ovarian Cancer (Advanced, Platinum-resistant) • Colorectal Cancer (Metastatic, 2nd -Line) • Malignant Melanoma (Unresectable/Metastatic) • Pancreatic Cancer (Unresectable/Metastatic)

Physician & Payer Forum: • Non-Small Cell Lung Cancer (EU) • The Dynamic Prostate Cancer Landscape (EU) • Attitudes to Cancer Immunotherapeutics (US) • Colorectal Cancer (US) • Impact of Payer-Imposed Strategies on Market Access in

NSCLC and Prostate Cancer (US) • Ovarian and Endometrial Cancer (US) • Breast Cancer in China and South Korea • Non-Small Cell Lung Cancer in China and South Korea • The Impact of Payer Policy on Prescribing in Non-

Hodgkin's Lymphoma and Multiple Myeloma (LATAM) • Patient Access to High Cost Therapies for Chronic

Myeloid Leukemia in Brazil and Mexico